Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study

BACKGROUND: We aimed to examine the immunogenicity pattern induced by the inactivated SARS-CoV-2 vaccine CoronaVac (Sinovac Life Sciences, Beijing, China) in SARS-CoV-2 seropositive patients with autoimmune rheumatic diseases compared with seropositive controls, seronegative patients with autoimmune...

Descripción completa

Detalles Bibliográficos
Autores principales: Aikawa, Nadia E, Kupa, Leonard V K, Pasoto, Sandra G, Medeiros-Ribeiro, Ana C, Yuki, Emily F N, Saad, Carla G S, Pedrosa, Tatiana, Fuller, Ricardo, Shinjo, Samuel K, Sampaio-Barros, Percival D, Andrade, Danieli C O, Pereira, Rosa M R, Seguro, Luciana P C, Valim, Juliana M L, Waridel, Filipe, Sartori, Ana Marli C, Duarte, Alberto J S, Antonangelo, Leila, Sabino, Ester C, Menezes, Paulo Rossi, Kallas, Esper G, Silva, Clovis A, Bonfa, Eloisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641960/
https://www.ncbi.nlm.nih.gov/pubmed/34901885
http://dx.doi.org/10.1016/S2665-9913(21)00327-1

Ejemplares similares

Ejemplares similares